TG Share Price

TG Share Price

NASDAQ: TGTX | Mid Cap | Healthcare
$63.35
-$1.50 (-2.31%) Last updated on 21 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • FAQs

TG Stock Performance

Open
$64.10
Prev. Close
$64.85
Circuit Range
N/A
Day Range
$63.19 - $65.29
Year Range
$26.80 - $67.92
Volume
1,87,635
Average Traded
$64.19

TG Share Price Today

As of 21 November 2026, TG Therapeutics, Inc.'s share price is $63.35. The stock opened at $64.10, compared to its previous close of $64.85. During today's trading session, TG Therapeutics, Inc.'s share price traded between $63.19 and $65.29, with an average price of $64.24. Over the past 52 weeks, the stock has recorded a high of $67.92 and a low of $26.80. In terms of performance, TG Therapeutics, Inc.'s share price has risen by 67.00% over the last six months and is up 90.41% on a year-on-year basis.

TG Share Price Chart

Line chart of the TG price trend over the selected period. The price fell overall, ranging from 63.15 to 65.52, ending at 63.35.
$63.19$65.29
L
Show Current Price
H

TG Stock Fundamentals & Key Indicators

Market Cap
$9.14B
PE Ratio (TTM)
92.46
Dividend Yield
0.00%
EPS (TTM)
$0.70
Revenue (TTM)
$616.29B
Return On Equity (TTM)
18.54%
Profit Margin
72.56%
Debt to Equity
1.30
Quarterly Earnings Growth YoY
140.71%

TG Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$192.57$204.92$240.34$259.94
Net Profit$23.04$19.78$7.78$55.46
Net Profit Margin11.96%9.65%3.24%21.34%
Income ChangeN/A-14.15%-60.67%612.85%

TG Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$2.79$233.66$329.00$616.29
Net Profit-$223.81$12.67$23.38$447.18
Net Profit Margin-8021.86%5.42%7.11%72.56%
Income ChangeN/A105.66%84.53%1812.66%

TG Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets432.4911.3311.6425.3
Current Assets630.76566.36317.94168.27
Total Assets1063.25577.69329.59193.57
Non Current Liabilities261.47264.65115.3781.78
Current Liabilities153.7690.6853.7253.2
Total Liabilities415.23355.33169.09134.99
Shareholders' Equity648.02222.36160.558.59

TG Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-24.77-40.52-31.41-176.17
Investing13.8-1.04-50.65-20.01
Financing-89.73128.5372.71-0.39

About TG

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

TG Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$61.75
$63.39
+3.61%
Oct 2026
$55.53
$61.18
+9.46%
Sep 2026
$52.51
$55.90
+0.33%
Aug 2026
$50.76
$55.71
+7.40%
Jul 2026
$55.16
$51.87
-5.59%
Jun 2026
$37.57
$54.94
+44.83%
May 2026
$33.38
$37.94
+12.28%
Apr 2026
$33.33
$33.78
+1.78%
Mar 2026
$29.50
$33.20
+10.28%
Feb 2026
$29.22
$30.10
+2.16%
Jan 2026
$29.57
$29.46
-1.21%
Dec 2025
$32.41
$29.82
-10.35%

TG Share Price FAQs